Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
about
microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and ChallengesAdrenocortical carcinoma (ACC): diagnosis, prognosis, and treatmentThe challenge of developmental therapeutics for adrenocortical carcinomaA phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.Emerging therapy for adrenocortical carcinoma.Adrenocortical carcinoma: the management of metastatic disease.Current and emerging therapeutic options in adrenocortical cancer treatment.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewAdrenal incidentalomas in cancer patients are not always "innocent": a case report and review of the literatureNovel targeted therapies in adrenocortical carcinoma.The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.Targeted therapy with kinase inhibitors in aggressive endocrine tumors.Management of adrenal cancer: a 2013 update.Metronomics: towards personalized chemotherapy?Diagnosis, treatment and outcome of adrenocortical cancer.Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study.5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide.Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the LiteratureEverolimus therapy for progressive adrenocortical cancer.STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo.Development of new preclinical models to advance adrenocortical carcinoma research.Adrenocortical carcinomaAvelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
P2860
Q26772746-55B96C77-53D5-4A72-9156-E8CF27AEEEE7Q26801839-1321BCFA-5B7A-4665-9329-8D953A6382C7Q28072970-5AD8C899-1AF5-4DEE-BDCD-4626B049D67FQ34017912-2767B59C-5970-4C65-9DCF-44898B285135Q34173001-FB9330E8-E802-4024-B9F8-88BB7F9AE3E0Q34431264-CAA6229C-F049-48FD-992E-9399F274C631Q35018399-16373A07-6088-409E-A1BC-D8F989BC1D8AQ36081865-EF48FA47-67F6-44F5-937D-DF2C6CD83121Q36183873-FF91FF92-1035-4182-B838-D595CF8D3529Q36270115-8D542A73-1FB5-4BDC-B69E-DFA09D2CC75BQ36804969-1D47C4BF-8EF1-462D-9FCB-A8DABB0F44C0Q37233378-1F0C1606-0C9E-414E-9E8C-75E9976DBEC7Q37681171-0DF6A89A-990E-4F78-9964-FF85F415E2FDQ38107011-D81E5D41-B40D-4A31-BD92-09DD9DC2B212Q38181425-AB21F2B7-C85E-4483-BCE2-86C2DB1D2561Q38218923-7168301B-0151-43C1-9F1D-F4453480131BQ38358503-C1A5AA21-5DFD-435F-8DCC-D97685D058F0Q38545507-736D67A6-F557-4ED7-9CA8-462B0CC1951DQ38640345-3279F86C-9502-4B8B-B1D6-73F0B2F68161Q38686201-0CE674AB-90D7-4C66-BA5B-266200DB40EEQ40862337-06CDE2A2-4C15-4263-A8AE-14670DB3D4D2Q41863971-825E7A3B-4AD0-4DA2-A951-70720E263E05Q43478917-C8B7EF3B-8154-4DE1-9176-B0B175F9CCC8Q47321196-3857F860-0181-46B8-8922-2161F125095BQ49676347-90BA531F-492E-42DA-8687-BB4296886DBEQ49681867-8B1DD016-0138-4202-9D53-1BCCF8BA4CCEQ57645859-DD2A0713-A0BC-4AF4-9C07-02B64297B9A3Q57803796-3C6EC649-E6E5-42D3-AFAB-E5904184142F
P2860
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@en
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@nl
type
label
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@en
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@nl
prefLabel
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@en
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@nl
P2093
P50
P356
P1476
Phase II study of weekly pacli ...... with adrenocortical carcinoma.
@en
P2093
Adriano Massimiliano Priola
Alfredo Berruti
Anna Ferrero
Arianna Ardito
Eric Baudin
Fulvia Daffara
Marco Volante
Mauro Papotti
Paola Perotti
Paola Sperone
P304
P356
10.1530/EJE-11-0918
P577
2011-12-21T00:00:00Z